NEW YORK (GenomeWeb) – Immunoassay firm Gyros and peptide synthesis company Protein Technologies said today that they have entered into a definitive merger agreement to form Gyros Protein Technologies.

The company will combine Gyro's microfluidics, systems development, and immunoassay experience with Protein Technologies' peptide synthesis expertise to provide sample prep, synthesis, and bioanalytical tools for biotherapeutics discovery, development, and bioprocessing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.